Neoadjuvant pembrolizumab benefits patients with high-risk...
Disclosures:Merck Sharp & Dohme sponsored this study. Schmid reports research funding from Astellas, AstraZeneca, Genentech/Roche, Medivation, Novartis and OncoGenex Pharmaceuticals. He also reports honoraria or consultant fees from Astr...